25 Cruzain, a cysteine protease of Trypanosoma cruzi, is a validated target for the treatment of 26 Chagas disease. Due to its high similarity in three-dimensional structure with human 27 cathepsins and their sequence identity above 70% in the active site regions, identifying potent 28 but selective cruzain inhibitors with low side effects on the host organism represents a 29 significant challenge. Here a panel of nitrile ligands with varying potencies against cathepsin 30 K, cathepsin L and cruzain, are studied by molecular dynamics simulations as both non-31 covalent and covalent complexes. Principal component analysis (PCA), identifies and 32 quantifies patterns of ligand-induced conformational selection that enable the construction 33 of a decision tree which can predict with high confidence a low-nanomolar inhibitor of each 34 of three proteins, and determine the selectivity for one against others. 35 36 Introduction 37 38 Cysteine proteases, specifically those belonging to the Papain family (1) (family C1 and Clan 39 CA, in the MEROPS(2) database classification), can be found in cellular lysosomes and the 40 extracellular matrix after cellular secretion (3,4), and are involved in many different biological 41 processes and pathways, including development and growth, cellular signalling, apoptosis, 42 pro-hormone processing, nutrition, invasion of host cells and others (5). Unsurprisingly then, 43 they are of significant interest to the pharmaceutical industry(6,7) and amongst these 44 enzymes are validated targets for the development of treatments for osteoporosis, cancer, 45 immune diseases and parasitic diseases (8) (e.g. malaria, Chagas disease (9), and 46 leishmaniasis). As a result of this interest there are currently a considerable number of small 47 molecule inhibitors of cysteine proteases, especially of human cathepsins,(10-12) 48 Trypanosoma cruzi cruzain, (13-15) and falcipains from Plasmodium falciparum (16,17). 49 50 Chagas Disease is a parasitic disease caused by the flagellated parasite Trypanosoma cruzi and 51 was described for the first time in 1909 by Carlos Chagas (18)(19)(20). Despite the high economic 52 cost of Chagas disease, estimated at 7 billion dollars per year (21) due to palliative treatment 53 and early retirement, this disease is neglected by the pharmaceutical industry. The current 54 available treatment is the drug benzonidazole, which was developed during the 1970s and 55 has severe side effects (22). The T. cruzi enzyme cruzipain (Enzyme Classification number 56 3.4.22.51) is abundant throughout the life cycle of the parasite and is particularly important 57 during the amastigote phase. Cruzipain is essential to parasite nutrition as well as during 58 differentiation phases and host cell invasion, when it activates inflammatory process and 59 degrades immunoglobulins. It is expressed as a zymogen consisting of catalytic, pre and pro 60 domains. The last is cleaved to obtain the mature enzyme, while the pre-domain, highly 61 glycosylated, is maintained as part of the enzyme and only released later to trigger an 62 immunogenic response in the host organism (23). The presence of this domain in cruzipain 63 differentiates it from human cathepsins (24). However, it has been shown that the cleavage 64 of the pre-domain does not affect the catalytic activity of the protein (25) and hence most 65 research focuses on the N-terminal catalytic domain, which when expressed heterologously 66 in Escherichia coli is named cruzain. Cruzain is composed of 215 residues of which Cys25 and 3 67 His159 are the catalytic dyad. It features three disulfide bonds distributed over the protein 68 that enhance extracellular stability and are also present in cathepsin enzymes. 69 70 Cysteine proteases are effectively inhibited by several classes of covalent and non-covalent 71 inhibitors (14,26). Covalent inhibitors typically present groups containing a reactive 72 electrophilic centre (warhead) susceptible to nucleophilic attack by the activated cysteine 73 present in the enzyme active site. Depending on the nature of the warhead, covalent bond 74 formation between the inhibitor and the protein may be irreversible or reversible. (27) 75 Examples of reversible covalent inhibitors are peptide-aldehydes, α-diketones, α-ketoesters, 76 α-ketoamides, α-keto acids and nitriles (28). In contrast, compounds such as peptidyl 77 diazomethyl ketones, fluoromethyl ketones, epoxides and vinyl sulfones are capable of 78 binding irreversibly to the catalytic cysteine, acting as "suicide" inhibitors.(29) Several non-79 covalent inhibitors of proteases have also been described in the literature, including the 80 analysis of the mode of binding of our cruzain inhibitor Neq0176.(14) However, few of them 81 exhibit comparable enzyme affinity to those acting via a covalent mechanism (30), with the 82 notable exception of a new (non-covalent) and reversible competitive inhibitor that inhibits 83 cruzain in nanomolar concentration and another one that also kills T. cruzi in low micromolar 84 range (31). 85 86 The rational design of selective, potent reversible covalent inhibitors of cysteine proteases is 87 complicated by their mechanism of action. Aspects of both their covalent and non-covalent 88 interactions must be considered, but how to do so remains an open question. We have 89 recently shown(32) that careful QM/MM calculations on the covalent binding of dipepdidyl 90 nitrile ligands to cruzain can correlate well with experimental binding data, but the procedure 91 is not suitable for high throughput use where the interactions of multiple ligands with 92 multiple enzymes requires to be evaluated. Recently, Waldner et al.(33) have shown that, for 93 a panel of serine proteases, substrate specificity that could not be understood from an 94 analysis of static (crystal) structures, was interpretable once the differential dynamics of the 95 proteins was considered. It is well established that any attempt to understand and optimise 96 a ligand-protein interaction must take into account protein flexibility (34) , (35). The two 97 limiting models for ligand-induced conformational change in a protein are induced fit and 98 conformational selection(36). The former supposes that the native, free, form of protein has 99 a preference for one or more specific conformations with which the ligand interacts, which 100 then induces and stabilize a new conformation of protein that was not accessed originally 101 (37). The latter hypothesises that the normal thermally-activated dynamics of the free protein 102 involves it spontaneously but transiently adopting the conformation appropriate for ligand 103 binding. In the presence of the ligand this state is captured and 'titrated out' of the 104 equilibrium distribution (38). These two limiting models make very different predictions 105 about the effect of ligand binding on the conformational dynamics of the protein, and thus 106 configurational entropy components of the binding free energy. The induced fit model 107 involves the ligand encouraging the protein to visit conformational states it did not sample in 108 the apo state -configurational entropy may tend to increase. In contrast, the conformational 109 selection model involves the ligand discouraging the protein from adopting certain 110 conformations, so configurational entropy may tend to decrease. Molecular simulation 111 methods can provide powerful insights into this process, (39) -(40), and so rationally guide 112 ligand design. 113
114 Here we use molecular dynamics simulations to investigate the effects of a range of nitrile-115 based cysteine protease inhibitors, with affinities ranging from the micromolar to nanomolar 116 range, on the conformational dynamics of the active sites of cathepsin K, cathepsin L, and 117 cruzain. We hypothesised that analysis of the ways in which different ligands perturb and limit 118 the intrinsic dynamics of the apo enzymes might give insights into the origins of affinity and 119 selectivity, and indeed this proves to be the case. Our approach is somewhat different from 120 that described by Waldner et al. but the outcomes are similar: with the aid of principal 121 component analysis (PCA), we identify and quantify patterns of ligand-induced 122 conformational selection that enable the construction of a decision tree which can predict 123 with high confidence a low-nanomolar inhibitor of each of three proteins and determine the 124 selectivity for one against others. (56) . The calculations were done 240 using default parameters. One PCA was performed for each of the ligands studied. Each PCA 241 included all relevant simulation data, taking a sample every 100ps. Thus, for each of ligands 242 ICR, ICK, ICL, and IKR, the PCA included: a) the data from the five replicate simulations of 243 cruzain, cathepsin K and cathepsin L in apo form; b) the data from the simulations of the same 244 three proteins when non-covalently complexed to the ligand; and c) the data from the 245 simulations of the same three proteins when covalently cross-linked to the ligand. In the case 246 of ligand BCR, since we only have binding data for the interaction of this ligand with cruzain, 247 the dataset for PCA contained just apo-cruzain, plus the non-covalent and covalent complexes 248 of BCR with cruzain. 249 250 To permit a full comparison of PCA results, a common subset of atoms was selected from 251 every trajectory as follows. Firstly, all residues in the reference cruzain-K777 complex 252 (PDB:2OZ2), that had at least one atom within 7 Å of the ligand were selected. Then by 253 structural alignment the corresponding residues in cathepsin K (PDB code 1MEM) and 254 cathepsin L (PDB: 2YJ2) were identified. At positions where the amino acid differed between 255 one protein and another, the maximum common subset of structurally equivalent atoms was 256 retained. 257 258 Conformational Distribution Analysis 259 For each ligand, we analysed the PCA data to observe, in the PC1/PC2 plane, the 260 conformational space sampled by the common subset of protein binding site atoms in the 261 apo, non-covalently bound, and covalently bound complexes. We found that for every ligand, 262 the sampling of the PC1/PC2 plane lay within a bounding box of -20 -20 Å in each dimension. 263 Therefore we calculated 2D histograms for each dataset within these limits, with a 1 Å 2 264 resolution (thus 20 x 20 bins). For each ligand we then defined three (potentially overlapping) 265 sets. The first, A, contains all bins that are sampled by the apo protein. The second, N, similarly 266 contains all bins sampled by the protein when non-covalently bound to the ligand. The third, 267 C, contains all bins sampled in the simulation of the relevant covalent complex. For all sets, 268 bins with less than 1% occupancy were ignored. Using standard set theory notation, the 269 number of samples in A is |A|, etc., the set of bins sampled in both the apoand non-covalent 270 simulations is A∩N, etc., and the number of samples in this intersection is |A∩N|, etc. 271 272 Results
274 Structural Analysis of Molecular Dynamics Simulations
275 Our 2-round, 5-replicate, MD protocol was designed to maximize the chance of obtaining a 276 "well-behaved" trajectory data set for each non-covalent ligand simulation. We expected that 277 simulations of ligand complexes that were known to have a high binding affinity would be 278 more likely to be stable than those where it was known the ligand was a poor inhibitor of the 279 protein, and in general this was what was observed. The two quality metrics were a) the 280 distance between the S atom of the catalytic cysteine and the C atom of the warhead nitrile; 281 and b) the RMSD of the ligand from its original, docked, conformation. The results obtained 282 are summarized in Table 2 and in S1-S5 Figs in supporting information. For ligands IKR, ICR, 283 and ICL, there appears some relationship between these metrics and binding affinity. 284 However for ICK the simulations suggest a poor geometry for the non-covalent complex with 285 cruzain, and a poor warhead geometry for the complex with CatK, despite the fact it is a good 286 (or reasonable) inhibitor of both enzymes. Conversely, the complex of BCR with cruzain 287 appears to have a good stability and geometry but is known to be a poor inhibitor. In this last 288 case, close inspection of the binding pose shows that though the nitrile-cysteine distance is 289 not long, the relative orientations of the groups are not conducive to nucleophilic attack, so 290 this may explain this anomaly. 291 292 293 Table 2 317 Results are presented in Error! Reference source not found., and in more detail in S9-S12 Figs 318 in the supporting information. In each case the PC1/PC2 space sampled by the apo protein is 319 indicated by the black dots, by red dots for when the protein is bound non-covalently to the 320 ligand, and by green dots when there is a covalent complex. Broadly speaking, we would 321 expect conformational selection-type behaviour to be manifested by a shrinkage in the 322 sampling within the boundaries of the previous state, while induced fit-type behaviour would 323 lead to a shift in the distribution so that previously unsampled states became populated, and 324 previously populated ones not. 366 It is interesting to observe that the behaviour of this ligand in complex with both cruzain and 367 cathepsin L protein is almost the same, but the PCA analysis here shows two different 368 patterns. The cruzain-ICK complex shows two sequential reductions in conformational space 369 covered by simulation, the first after noncovalent ligand binding and the second one after the 370 formation of the covalent bond, suggesting the ligand induces a conformational selection 371 from all possible states of the protein to a specific one that permits a better interaction with 372 the ligand. In contrast, the conformational spaces covered by cathepsin L in both the free 373 state and in noncovalent complex with ICK are almost the same, suggesting the protein does 374 not properly recognize the ligand. In the (maybe hypothetical) covalent complex, the enzyme 375 is forced to adapt to ligand because of the imposition of bond formation between Cys25 and 376 ligand nitrile. 377 378 Lastly, in the case of the ICL -cathepsin K system we see that, remarkably, the conformational 379 space accessed by the noncovalent complex smaller than that for the covalent complex, what 380 may suggest the covalent form ligand induces the protein to a less stable conformation in 381 comparison with noncovalent complex, maybe due to some steric repulsion. 382
Development of a Decision Tree to Identify Strong and Weak 384
Complexes 385 We hypothesised that it might be possible to convert our observations regarding the effects 386 of strong and weak ligands on the dynamics of cysteine protease active sites into a predictive 387 tool. From the parameters obtained by application of set theory to the PCA data (see methods 388 section and S14 Table of the supporting information), a decision tree to identify strong and 389 weak complexes (pK i or pIC 50 above and below 7, respectively) was built (Fig 3) that classified 390 correctly all twelve complexes from training set. 412 higher up in the decision tree) that the noncovalent form of ligand may be forcing the protein 413 to a conformation not accessed by apo form. This would be an indicative of induced-fit model 414 for the system. In our case, for cysteine proteases in complex with dipeptidyl nitriles, a value 415 above 50% for this rule identifies the ICL-cathepsin K complex, which is defined as a weak 416 complex. This result strengthens the hypothesis that conformational selection behaviour for 417 ligands of cysteine proteases is a mark of strong inhibitors. 418 419 Test of the Decision Tree 420 To test the decision tree, we applied it to four ligands from our in-house collection of 421 dipeptidyl nitriles (Fig 1 and Table 1 ). Two of these are potent inhibitors of cruzain, one is 422 moderate (but on the basis of our <500nM cut-off, is classified as active), and one is poor. 423 Simulations of these ligands bound both non-covalently and covalently to cruzain were 424 conducted using exactly the same protocol as described above, and the data analysed in the 425 same way. We predict that these cysteine proteases make use of the conformational selection model for 441 ligand selectivity. We observe that the active site in its free form accesses an extended 442 conformational space that is reduced stepwise by the noncovalent, then covalent, binding of 443 ligands. Besides the space reduction, we observe the covalent space lies within the 444 noncovalent space which in turn lies within the free protein space, a typical behaviour of 445 proteins that obey the conformational selection model. Furthermore, this pattern is only 446 observed for complexes with IC50 or Ki below 500 nM. For weak complexes, the 447 conformational space sampled by protein active site in covalent simulations is not a subset of 448 the noncovalent space. This mode of analysis has predictive power: a set theory treatment 449 of PCA distributions can generate a decision tree capable of categorizing the activity of 450 different dipeptidyl nitriles against at least papain-family proteins. 451 452 Simpler metrics based purely on analysis of the non-covalent complexes, e.g. RMSD of the 453 ligand from the conformation suitable for cross-linking, or distance between the key cysteine 454 S and nitrile C atoms, are not reliable. At a higher level, MMGBSA binding energy calculations 455 are also not predictive. In part this is not unexpected, since these approaches do not deal in 456 any detail with the process of transforming from the non-covalent to the covalent complex. 457 What our studies reveal is that this step has energetics that do not necessarily correlate with
